A PHASE 1/2 MULTICENTER, OPEN-LABEL STUDY TOASSESS THE SAFETY, PHARMACOKINETICS ANDEFFICACY OF CC-92480 MONOTHERAPY AND INCOMBINATION WITH DEXAMETHASONE INSUBJECTS WITH RELAPSED AND REFRACTORYMULTIPLE MYELOMA
MD Anderson Study Status
This is an open-label, multi-center, international, Phase 1/2 study to assess the safety, PK and efficacy of CC-92480 monotherapy and in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma (RRMM). RRMM patient previously treated with at least 3 prior regimens including lenalidomide or pomalidomide, a proteasome inhibitor and a CD38 antibody will be eligible.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
For general questions about clinical trials: